Eculizumab treatment for renal failure in a pediatric patient with COVID-19

J Nephrol. 2020 Dec;33(6):1373-1376. doi: 10.1007/s40620-020-00858-2. Epub 2020 Sep 26.

Abstract

While there are increasing reports of acute kidney injury among hospitalized adults with COVID-19, there is still limited information on renal complications associated with COVID-19 in children. The cause of kidney involvement in COVID-19 is likely multifactorial, and appears to involve a complex process, including complement dysregulation and thrombotic microangiopathy. We present a pediatric case of COVID-19 and renal failure due to thombotic microangiopathy, successfully treated with eculizumab.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • COVID-19 / epidemiology*
  • Comorbidity
  • Complement Inactivating Agents / therapeutic use
  • Female
  • Humans
  • Kidney Failure, Chronic / epidemiology
  • Kidney Failure, Chronic / therapy*
  • Pandemics
  • Renal Dialysis / methods*
  • SARS-CoV-2*

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • eculizumab